EMAIL THIS PAGE TO A FRIEND

Molecular cancer therapeutics

Potency-matched Dual Cytokine-Antibody Fusion Proteins for Cancer Therapy.


PMID 28716814

Abstract

A novel biopharmaceutical, consisting of the F8 mAb (specific to a splice isoform of fibronectin) simultaneously fused to both TNF and IL2, was found to react with the majority of solid tumors and hematologic malignancies in mouse and man, but not with healthy adult tissues. The product selectively localized to neoplastic lesions